Production (Stage)
Avalo Therapeutics, Inc.
AVTX
$3.75
-$0.16-4.09%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -22.89% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -22.89% | |||
| Cost of Revenue | 6.75% | -14.75% | |||
| Gross Profit | -10.59% | 14.42% | |||
| SG&A Expenses | 5.98% | 22.10% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.64% | 3.00% | |||
| Operating Income | -10.20% | -3.50% | |||
| Income Before Tax | 62.69% | -253.00% | |||
| Income Tax Expenses | -92.98% | 914.29% | |||
| Earnings from Continuing Operations | 62.79% | -253.40% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 62.79% | -253.40% | |||
| EBIT | -10.20% | -3.50% | |||
| EBITDA | -9.75% | -3.24% | |||
| EPS Basic | 63.61% | -448.97% | |||
| Normalized Basic EPS | 63.70% | -182.94% | |||
| EPS Diluted | 63.61% | -21.26% | |||
| Normalized Diluted EPS | 63.70% | -261.27% | |||
| Average Basic Shares Outstanding | 2.77% | 84.47% | |||
| Average Diluted Shares Outstanding | 2.77% | -5.13% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||